UBS upgrades IQVIA stock to Strong Buy rating

Published on 10/02/2026 at 17:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Truist lifted its target from USD 300.00 to USD 329.00 on September 28, 2026. IQVIA stock costs EUR 229.55 versus EUR 231.90, down 1.01 percent.

Aquarell-Stadtpanorama mit modernen Bürogebäuden und Flussreflexionen bei Sonnenuntergang — IQVIA Holdings Firmensitz US46266C1053 als sanftes Aquarell mit Flussreflexion und warmem Abendhimmel über der Stadt, Illustration mit AI erstellt.

IQVIA Holdings (ISIN US46266C1053) was upgraded by UBS Group to a Strong Buy rating, while IQVIA stock was trading at EUR 229.55 at Lang & Schwarz on October 2, 2026. The price was down 1.01 percent versus the EUR 231.90 prior close dated October 1, 2026, giving the analyst move a mixed same-day market backdrop.

UBS adds a fresh analyst signal

As MarketBeat reported on October 1, 2026, UBS Group upgraded IQVIA to Strong Buy in a research note issued on Wednesday. The same report cited a Moderate Buy consensus and an average analyst target of USD 264.31, while the latest target action came from Truist.

According to Investing.com on September 28, 2026, Truist Securities raised its target from USD 300.00 to USD 329.00 and kept a Buy rating. The increase was tied to healthy industry demand, improving biotech activity and operating performance, but the target is stated in USD and is not a replacement for the German-market EUR quote.

Second-quarter growth met demand

IQVIA's second-quarter 2026 adjusted earnings per share reached USD 3.15, up 12.10 percent from USD 2.81 a year earlier and 4.30 percent above the USD 3.02 consensus estimate, according to Zacks. Revenue increased 8.70 percent year over year to USD 4.36 billion and exceeded the USD 4.29 billion consensus estimate by 1.60 percent.

The operating indicators were stronger than the GAAP result alone suggests. Research and Development Solutions produced USD 3.15 billion of net new bookings in the second quarter, up 19.00 percent year over year, while trailing twelve-month bookings rose 13.00 percent to USD 11.30 billion, according to Zacks. Contracted backlog stood at USD 34.20 billion, supporting visibility into clinical research revenue.

Stock stays below its yearly high

IQVIA was last at USD 258.58 on the NYSE on October 2, 2026 at 11:20 a.m. ET, while its 52-week range was USD 154.50 to USD 277.40. The Lang & Schwarz price therefore provides the relevant EUR perspective for German investors, while the NYSE figures show the underlying home-market context.

IQVIA's second-quarter 2026 operating cash flow was USD 558.00 million, up 26.00 percent year over year, and free cash flow reached USD 360.00 million, up 23.30 percent, according to Zacks. That combination of bookings growth, cash generation and higher analyst targets is the central counterweight to the stock's leverage and its 1.01 percent daily decline.

EUR quote sets the German view

IQVIA stock was trading at EUR 229.55 at Lang & Schwarz on October 2, 2026 at 5:09 p.m. CEST, down 1.01 percent versus the EUR 231.90 prior close at Lang & Schwarz on October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of IQVIA Holdings stock.